Accelerant debuted on the NYSE with a 36% surge, but shares have since fallen 38% below the IPO price. ARX positions itself as a 'data-driven risk exchange,' aiming to transform the specialty ...
Citizens JMP analyst Matthew Carletti upgraded Accelerant (ARX) to Outperform from Market Perform with a $20 price target The weakness in the shares since the company’s July initial public offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback